Focal Therapy for Prostate Cancer: Possibilities and Limitations

European Urology

Volumn 58, Issue 1, 2010, Pages 57-64

  Eggener, Scott ^a   Salomon, Georg ^b   Scardino, Peter T ^c   De la Rosette, Jean ^d   Polascik, Thomas J ^e   Brewster, Simon ^f  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e DUKE UNIVERSITY   (United States)

^f CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Cryoablation; Focal therapy; High intensity focused ultrasound; Laser induced interstitial thermotherapy; Photodynamic therapy; Prostate cancer

Indexed keywords

ALTERNATIVE MEDICINE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER THERAPY; CRYOTHERAPY; DIAGNOSTIC IMAGING; FOCAL THERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INFORMATION RETRIEVAL; INTESTINE FUNCTION; LASER THERMOTHERAPY; MEDLINE; METASTASIS; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SAMPLE SIZE; SEXUAL FUNCTION; STUDY DESIGN; URINARY TRACT FUNCTION;

ABLATION TECHNIQUES; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEOPLASM STAGING; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77952883054     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.03.034     Document Type: Review

References (68)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
2. Sakr W.A., Grignon D.J., Crissman J.D., et al. High-grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8 (1994) 439-443
3. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
4. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
5. Bill-Axelson A., Holmberg L., Filen F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100 (2008) 1144-1154
6. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
7. Stephenson A., Klein E., Kattan M., Han M., and Partin A. Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. J Clin Oncol 27 (2009) 15s Abstract 5007
8. Tewari A., Johnson C.C., Divine G., et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 171 (2004) 1513-1519
9. Bittner N., Merrick G.S., Galbreath R.W., et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 72 (2008) 433-440
10. Iczkowski K.A., Hossain D., Torkko K.C., et al. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 71 (2008) 1166-1171
11. Kassouf W., Nakanishi H., Ochiai A., Babaian K.N., Troncoso P., and Babaian R.J. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. J Urol 178 (2007) 111-114
12. Kikuchi E., Scardino P.T., Wheeler T.M., Slawin K.M., and Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer?. J Urol 172 (2004) 508-511
13. Stark J.R., Perner S., Stampfer M.J., et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. J Clin Oncol 27 (2009) 3459-3464
14. Hernandez D.J., Nielsen M.E., Han M., et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 72 (2008) 172-176
15. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165-8169
16. Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Outcomes of localized prostate cancer following conservative management. JAMA 302 (2009) 1202-1209
17. Dall'Era M.A., Cooperberg M.R., Chan J.M., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112 (2008) 1650-1659
18. Eggener S.E., Mueller A., Berglund R.K., et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 181 (2009) 1635-1641 discussion 1641
19. Warlick C., Trock B.J., Landis P., Epstein J.I., and Carter H.B. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98 (2006) 355-357
20. Latini D.M., Hart S.L., Knight S.J., et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 178 (2007) 826-831 discussion 831-2
21. van den Bergh R.C., Essink-Bot M.L., Roobol M.J., et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer 115 (2009) 3868-3878
22. Wise A.M., Stamey T.A., McNeal J.E., and Clayton J.L. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60 (2002) 264-269
23. Noguchi M., Stamey T.A., McNeal J.E., and Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170 (2003) 459-463
24. Arora R., Koch M.O., Eble J.N., Ulbright T.M., Li L., and Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100 (2004) 2362-2366
25. Challacombe B.J., Murphy D.G., Zakri R., and Cahill D.J. High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. BJU Int 104 (2009) 200-204
26. Crawford E.D., and Barqawi A. Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer. Oncology (Williston Park) 21 (2007) 27-32 discussion 33-4, 39
27. De la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. In press.
28. Eggener S.E., Scardino P.T., Carroll P.R., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 178 (2007) 2260-2267
29. Lambert E.H., Bolte K., Masson P., and Katz A.E. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69 (2007) 1117-1120
30. Lindner U., Weersink R.A., Haider M.A., et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 182 (2009) 1371-1377
31. Muto S., Yoshii T., Saito K., Kamiyama Y., Ide H., and Horie S. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38 (2008) 192-199
32. Onik G., Vaughan D., Lotenfoe R., Dineen M., and Brady J. The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 26 (2008) 500-505
33. Tsakiris P., Thuroff S., de la Rosette J., and Chaussy C. Transrectal high-intensity focused ultrasound devices: a critical appraisal of the available evidence. J Endourol 22 (2008) 221-229
34. Shappley III W.V., Kenfield S.A., Kasperzyk J.L., et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 27 (2009) 4980-4985
35. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24 (2006) 46-50
36. Carter H.B., Kettermann A., Warlick C., et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178 (2007) 2359-2364 discussion 2364-5
37. Mayes JM, Mouraviev V, Sun L, Tsivian M, Madden JF, Polascik TJ. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol. In press. doi:10.1016/j.urolonc.2009.03.011.
38. Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int. In press.
39. Nogueira L., Wang L., Fine S.W., et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 75 (2010) 472-477
40. Thong A.E., Shikanov S., Katz M.H., et al. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy-can we predict adverse pathological outcomes?. J Urol 180 (2008) 2436-2440
41. Berglund R.K., Masterson T.A., Vora K.C., Eggener S.E., Eastham J.A., and Guillonneau B.D. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 180 (2008) 1964-1967 discussion 1967-8
42. Ohori M., Eastham J., Koh H., Kuroiwa K., Slawin K., and Wheeler T. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)-an analysis of radical prostatectomy (RP) specimens. J Urol 175 Suppl (2006) 507 Abstract 1574
43. Gburek B.M., Kollmorgen T.A., Qian J., D'Souza-Gburek S.M., Lieber M.M., and Jenkins R.B. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol 157 (1997) 223-227
44. Qian J., Bostwick D.G., Takahashi S., et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55 (1995) 5408-5414
45. Eastham J.A., Riedel E., Scardino P.T., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695-2700
46. Fall K., Garmo H., Andren O., et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99 (2007) 526-532
47. Abouassaly R., Lane B.R., and Jones J.S. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology 71 (2008) 573-577
48. Klotz L., Zhang L., Lam A., Nam R., Mamedov A., and Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28 (2010) 126-131
49. Vos P.C., Hambrock T., Hulsbergen-van de Kaa C.A., Futterer J.J., Barentsz J.O., and Huisman H.J. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys 35 (2008) 888-899
50. Haider M.A., van der Kwast T.H., Tanguay J., et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 189 (2007) 323-328
51. Villers A., Puech P., Mouton D., Leroy X., Ballereau C., and Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176 (2006) 2432-2437
52. Zelhof B., Lowry M., Rodrigues G., Kraus S., and Turnbull L. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int 104 (2009) 621-627
53. Wink M., Frauscher F., Cosgrove D., et al. Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur Urol 54 (2008) 982-993
54. Frauscher F., Klauser A., Volgger H., et al. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 167 (2002) 1648-1652
55. Pelzer A., Bektic J., Berger A.P., et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 173 (2005) 1926-1929
56. Mitterberger M., Pinggera G.M., Horninger W., et al. Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol 178 (2007) 464-468 discussion 468
57. Halpern E.J., Rosenberg M., and Gomella L.G. Prostate cancer: contrast-enhanced us for detection. Radiology 219 (2001) 219-225
58. Pallwein L., Mitterberger M., Struve P., et al. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol 17 (2007) 2278-2285
59. Salomon G., Köllerman J., Thederan I., et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol 54 (2008) 1354-1362
60. Braeckman J., Autier P., Soviany C., et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 102 (2008) 1560-1565
61. Hodge K.K., McNeal J.E., Terris M.K., and Stamey T.A. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142 (1989) 71-74 discussion 74-5
62. King C.R., McNeal J.E., Gill H., and Presti Jr. J.C. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys 59 (2004) 386-391
63. Onik G., Miessau M., and Bostwick D.G. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 27 (2009) 4321-4326
64. San Francisco I.F., DeWolf W.C., Rosen S., Upton M., and Olumi A.F. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 169 (2003) 136-140
65. Merrick G.S., Taubenslag W., Andreini H., et al. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int 101 (2008) 1524-1529
66. Ahmed H.U., Zacharakis E., Dudderidge T., et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 101 (2009) 19-26
67. Bahn D.K., Silverman P., Lee Sr. F., Badalament R., Bahn E.D., and Rewcastle J.C. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 20 (2006) 688-692
68. Babaian R.J., Donnelly B., Bahn D., et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 180 (2008) 1993-2004